- Home
- IPHA vs PLCE Comparison
IPHA vs PLCE Comparison
Compare IPHA & PLCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- PLCE
- Stock Information
- Founded
- IPHA 1999
- PLCE 1969
- Country
- IPHA France
- PLCE United States
- Employees
- IPHA N/A
- PLCE N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- PLCE Clothing/Shoe/Accessory Stores
- Sector
- IPHA Health Care
- PLCE Consumer Discretionary
- Exchange
- IPHA Nasdaq
- PLCE Nasdaq
- Market Cap
- IPHA 160.1M
- PLCE 128.9M
- IPO Year
- IPHA 2019
- PLCE 1997
- Fundamental
- Price
- IPHA $1.74
- PLCE $5.00
- Analyst Decision
- IPHA Strong Buy
- PLCE Hold
- Analyst Count
- IPHA 1
- PLCE 1
- Target Price
- IPHA $11.00
- PLCE $6.00
- AVG Volume (30 Days)
- IPHA 11.2K
- PLCE 794.8K
- Earning Date
- IPHA 09-11-2025
- PLCE 06-06-2025
- Dividend Yield
- IPHA N/A
- PLCE N/A
- EPS Growth
- IPHA N/A
- PLCE N/A
- EPS
- IPHA N/A
- PLCE N/A
- Revenue
- IPHA $20,831,349.00
- PLCE $1,360,516,000.00
- Revenue This Year
- IPHA $209.83
- PLCE N/A
- Revenue Next Year
- IPHA $83.15
- PLCE $1.47
- P/E Ratio
- IPHA N/A
- PLCE N/A
- Revenue Growth
- IPHA N/A
- PLCE N/A
- 52 Week Low
- IPHA $1.29
- PLCE $3.66
- 52 Week High
- IPHA $3.51
- PLCE $19.74
- Technical
- Relative Strength Index (RSI)
- IPHA 42.70
- PLCE 56.41
- Support Level
- IPHA $1.71
- PLCE $4.85
- Resistance Level
- IPHA $1.90
- PLCE $4.72
- Average True Range (ATR)
- IPHA 0.08
- PLCE 0.29
- MACD
- IPHA 0.00
- PLCE 0.18
- Stochastic Oscillator
- IPHA 47.62
- PLCE 97.13
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.